monitor for immune reconstitution syndrome; liver function monitoring required in patients with hepatitis

hypersensitivity reaction — requires immediate medical attention; hepatotoxicity — requires immediate medical attention

indicated to support viral load reduction in patients with human immunodeficiency virus infection, to target viral replication.

Dolutegravir inhibits the human immunodeficiency virus integrase enzyme by binding to the active site and blocking the strand transfer step of retroviral deoxyribonucleic acid integration, which is essential for the viral replication cycle.

Pregnancy: Use may be considered if benefits outweigh risks, particularly in pregnancy. Breastfeeding: HIV-positive mothers should not breastfeed due to transmission risk.